Balyasny Asset Management
VBIV

Balyasny Asset Management’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Balyasny Asset Management’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-725
Closed -$18K – 3359
2022
Q2 		$18K Buy
+725
New +$24.7K ﹤0.01% 2501
2021
Q4 		– Sell
-29,135
Closed -$2.72M – 2666
2021
Q3 		$2.72M Buy
+29,135
New +$2.77M 0.01% 1028

Other funds holding VBIV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Balyasny Asset Management's VBIV Position: Q3 2022 in Review

Balyasny Asset Management sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2022, closing a stake of 725 shares — an estimated $18K sold.

Balyasny Asset Management first reported a position in VBIV in Q3 2021 and held it in 2 quarters. The position peaked at $2.72M in Q3 2021. 127 funds tracked by Wall St. Rank hold VBIV as of Q3 2022.

  • Balyasny Asset Management reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 725 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2022, an estimated $18K.
  • Balyasny Asset Management first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2021 and held it in 2 quarters.
  • Balyasny Asset Management's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $2.72M in Q3 2021.
  • 127 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.